NCT07151417View on ClinicalTrials.gov

Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Knee OsteoarthritisMusculoskeletal DiseaseSurgery
Interventions
DRUG

PAI

Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg

DRUG

PAI + steroid

Standard PAI + 40mg methylprednisolone (n = 40)

DRUG

PAI + zilretta

Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)

Trial Locations (1)

20889

Walter Reed National Military Medical Center, Bethesda

All Listed Sponsors
lead

Walter Reed National Military Medical Center

FED

NCT07151417 - Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | Biotech Hunter | Biotech Hunter